Notes - Consolidated Statement Of Comprehensive Income

HISAMITSU PHARMACEUTICAL CO.,INC. - Filing #7726293

Concept 2017-03-01 to
2018-02-28
2017-03-01 to
2018-02-28
Notes - Consolidated statement of comprehensive income
Notes - Consolidated single statement of comprehensive income
Major components of selling, general and administrative expenses
Research and development expenses included in general and administrative expenses and manufacturing costs for period

※2 (前連結会計年度)

   一般管理費に含まれる研究開発費は14,378百万円です。

なお、製造費用に含まれる研究開発費はありません。

   (当連結会計年度) 

   一般管理費に含まれる研究開発費は15,076百万円です。

なお、製造費用に含まれる研究開発費はありません。

Notes regarding impairment losses
Notes regarding reclassification adjustments and tax effects relating to other comprehensive income

Talk to a Data Expert

Have a question? We'll get back to you promptly.